Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's improved financial standards and is expected to enhance its visibility among institutional investors, improve liquidity, and broaden market recognition. Trading under the ticker BLTE began on October 19, 2026. The company aims to leverage this milestone to drive growth and advance its lead drug candidate, tinlarebant, which targets Stargardt disease and other retinal conditions.
Belite Bio's uplisting to the Nasdaq Global Select Market provides context for readers interested in health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 17:11 WIB: out of 150 priced US health stocks, 69 rose and 45 fell. Among notable movers, Amneal Pharmaceuticals Inc. (AMRX) traded at USD 19.55 with a 1-day change of +1.93%, and the typical hold time on Pluang for AMRX is 10 days.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
ATEN International honored TD SYNNEX with its 2026 Best Sales Performance Award, recognizing exceptional sales results and strong partnership. The award highlights TD SYNNEX's role in expanding market reach and driving growth for ATEN's technology so...
